Logo image
Sjögren syndrome with associated lymphocytic interstitial pneumonia successfully treated With tacrolimus and abatacept as an alternative to rituximab
Journal article   Peer reviewed

Sjögren syndrome with associated lymphocytic interstitial pneumonia successfully treated With tacrolimus and abatacept as an alternative to rituximab

G. Thompson, A. McLean-Tooke, J. Wrobel, M. Lavender and M. Lucas
Chest, Vol.153(3), pp.e41-e43
2018
url
Link to Published Version *Subscription may be requiredView

Abstract

Interstitial lung disease (ILD) is a significant complication of Sjögren syndrome (SS) associated with increased morbidity and mortality. The mainstay of treatment remains corticosteroid administration, with or without additional immunosuppressive therapies. Preliminary studies in SS have shown benefit in glandular and serologic parameters following treatment with the CTLA4 immunoglobulin fusion protein abatacept. Topical tacrolimus has been effective for ocular symptoms in SS, but systemic therapy has not been reported. We describe the first case, to our knowledge, of the successful use of a combination of systemic tacrolimus and abatacept in severe refractory SS and related ILD.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.106 Rheumatology
1.106.1420 Sjogren's Syndrome
Web Of Science research areas
Critical Care Medicine
Respiratory System
ESI research areas
Clinical Medicine
Logo image